Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
It is suggested that the NOD2 gene product confers susceptibility to Crohn's disease by altering the recognition of these components and/or by over-activating NF-kB in monocytes, thus documenting a molecular model for the pathogenic mechanism of Crohn’s disease that can now be further investigated.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.
- M. Silverberg, J. Satsangi, B. Warren
- MedicineCanadian journal of gastroenterology = Journal…
- 1 September 2005
The introduction of a widely acceptable clinical subclassification is strongly advocated, which would allow detailed correlations among serotype, genotype and clinical phenotype to be examined and confirmed in independent cohorts of patients and, thereby, provide a vital foundation for future work.
Infliximab for induction and maintenance therapy for ulcerative colitis.
Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Infliximab, azathioprine, or combination therapy for Crohn's disease.
Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or inflIXimab monotherapy were more likely to have a corticosteroid-free clinical remission than those receiving azATHioprine monotherapy.
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis and the frequency of adverse events was similar in the vedolIZumab and placebo groups.
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Adalimumab was well-tolerated, with a safety profile consistent with previous experience with the drug, and was significantly more effective than placebo in maintaining remission in moderate to severe CD through 56 weeks.
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.